Maciej Kujawski
Overview
Explore the profile of Maciej Kujawski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
2978
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Development of Anti-CEA C2 Domain-Deleted Antibody (M5A∆C2) for the PET Imaging of Colorectal Cancer
Jitender J, Hong T, Sherman A, Wong P, Aniogo E, Kujawski M, et al.
Mol Imaging Biol
. 2025 Mar;
PMID: 40085171
Purpose: Recombinant antibody fragments represent a novel class of in vivo biological immunoPET imaging agents. This study developed a series of anti-carcinoembryonic antigen (CEA) C2 domain-deleted antibodies to evaluate their...
2.
Aniogo E, Kujawski M, Awuah D, Cha S, Espinosa R, Hui S, et al.
Front Immunol
. 2025 Jan;
15:1499471.
PMID: 39759518
Introduction: Although CAR-T cell therapy has limited efficacy against solid tumors, it has been hypothesized that prior treatment with Image-Guided Radiation Therapy (IGRT) would increase CAR-T cell tumor infiltration, leading...
3.
Fleckenstein J, Najjar S, Zimmermann W, Hauck C, Nguyen Q, Mejias-Luque R, et al.
Eur J Clin Invest
. 2024 Dec;
54 Suppl 2:e14355.
PMID: 39674873
No abstract available.
4.
Centonze M, Fiori V, Kujawski M, Li L, Wong P, Williams L, et al.
PLoS One
. 2024 Feb;
19(2):e0295345.
PMID: 38346003
Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1), a homotypic cell adhesion molecule glycoprotein with apical expression on normal epithelial cells and activated lymphocytes, is overexpressed on many tumors and acts as...
5.
Williams L, Li L, Yazaki P, Wong P, Hong T, Poku E, et al.
Cancer Med
. 2024 Feb;
13(3):e6909.
PMID: 38317590
Background: The potent immune effects of interleukin-2 (IL-2) for cancer therapy can be increased by genetic fusion of IL-2 to the Fc domain of an antibody (IL-2-Fc) or tumor targeted...
6.
Awuah D, Li L, Williams L, Urak R, Kujawski M, Forman S, et al.
Sci Rep
. 2023 Nov;
13(1):20853.
PMID: 38012196
Bispecific T cell engaging antibodies (bsAbs) have emerged as novel and powerful therapeutic agents for redirecting T cells towards antigen-specific tumor killing. The cell surface glycoprotein and SLAM family member,...
7.
Williams L, Li L, Yazaki P, Wong P, Miller A, Hong T, et al.
Biotechnol J
. 2023 Jun;
18(9):e2300115.
PMID: 37300381
Background: Immunocytokines (ICKs) are antibody directed cytokines produced by genetic fusion of an antibody to a cytokine. Methods: We now show that antibodies conjugated by click chemistry to interleukin-2 (IL-2)-Fc...
8.
Williams L, Dery K, Lee W, Li H, Shively J, Kujawski M
J Immunol Methods
. 2022 Jul;
508:113322.
PMID: 35843266
Elucidation of the function of gamma delta T cells (γδ T cells) requires robust models that show how γδ T cells are commonly involved in inflammation, since very little is...
9.
Minnix M, Kujawski M, Poku E, Yazaki P, Wong J, Shively J
J Nucl Med
. 2022 Jun;
63(12):1859-1864.
PMID: 35772959
Targeted α-therapy (TAT) delivers high-linear-transfer-energy α-particles to tumors with the potential to generate tumor immune responses that may be augmented by antigen-targeted immunotherapy. This concept was evaluated in immunocompetent carcinoembryonic...
10.
Kujawski M, Li L, Li H, Yazaki P, Swiderski P, Shively J
Biotechnol J
. 2021 Nov;
17(2):e2100389.
PMID: 34773368
Background: Genetic engineered Bispecific T-cell engagers (BiTEs) generate potent cytotoxic effects. Methods: Alternately, click chemistry engineered, dual specific bivalent Bispecific T-cell engaging antibodies (dbBiTEs) on T-cell surfaces can be generated...